Drug Trial Radar · NCT01613846
Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
Last checked: Nov 20, 2026Latest source record: Apr 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
544
Planned (sponsor's estimate)
Start
May 2012
Primary completion
Oct 30, 2016
Sponsor
- Lead sponsor
- Technical University of MunichAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 7, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Sorafenib and pazopanib are both effective and promising treatments for advanced Renal Cell Carcinoma (RCC). Both drugs are registered for this indication. No prospective comparative data in advanced RCC (or other indications) have been published. A search in the clinicaltrials.gov database did not reveal any planned or ongoing studies. As sequential therapy is now the standard of treatment for advanced RCC it is important to evaluate in clinical trials what the value of different sequential strategies is. This needs to be done every time new agents are introduced into the treatment armamentarium. As there are no data yet on the sequential use of sorafenib followed by pazopanib or vice versa, this sequence, however, will most certainly be used in daily practice, it is required to examine efficacy and safety of this sequential approach in a clinical trial in a randomized setting. Therefore, the investigators have designed an open randomized study in patients not previously treated for advanced RCC. Suitable patients will be randomized (1:1) in 2 groups.
Conditions
- Renal Cell Carcinoma
Interventions
Sorafenib+PazopanibDrug
Sorafenib (first-line) followed by Pazopanib (second-line)
Pazopanib+SorafenibDrug
Pazopanib (first-line) followed by Sorafenib (second-line)
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate if progression-free survival from randomization to progression or death during second-line therapy (Total PFS) of sorafenib followed by pazopanib is non-inferior compared to pazopanib followed by sorafenib.Time frame: 4 years
Locations
72 sites in 3 countries. Site status is shown where the registry gives one.
Medizinische Universität Innsbruck
Innsbruck, Austria
A. ö. Bezirkskrankenhaus Kufstein
Kufstein, Austria
AKH Linz GmbH
Linz, Austria
LKH Salzburg
Salzburg, Austria
Universitätsklinikum Aachen, Urologische Klinik
Aachen, Germany
Gesundheitszentrum St. Marien GmbH
Amberg, Germany
Praxis für Urologie
Berlin, Germany
Charite Campus Virchow Klinikum / Klein. Für Innere Med / Onkologie/Hämatologie
Berlin, Germany
Gemeinschaftspraxis Pott / Tirier / Hannig - Onkologie
Bottrop, Germany
Urologie im Schlosscarrée Braunschweig
Braunschweig, Germany
Klinikum Bremen-Mitte gGmbH
Bremen, Germany
Bethanien Krankenhaus Chemnitz gGmbH
Chemnitz, Germany
Überörtliche Gemeinschaftspraxis
Cologne, Germany
Onkologische Gemeinschaftspraxis Dörfel/Göhler
Dresden, Germany
Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden
Dresden, Germany
Urologische Gemeinschaftspraxis
Duisburg, Germany
Krankenhaus Düren gGmbH
Düren, Germany
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
Urologische Facharztpraxis
Eisleben Lutherstadt, Germany
Urologie Neandertal - Ortsübergreifende Gemeinschaftspraxis für Urologie
Erkrath, Germany
Waldkrankenhaus St. Marien
Erlangen, Germany
St.-Antonius-Hospital in Eschweiler / Klinik f. Hämatologie und Onkologie
Eschweiler, Germany
Hämato-onkologische Gemeinschaftspraxis
Essen, Germany
Onkozentrum Freiberg
Freiberg, Germany
Praxis für interdisziplinäre Onkologie & Hämatologie
Freiburg im Breisgau, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
MVZ Osthessen GmbH
Fulda, Germany
Gem.praxis Dres. J. Wilke, H. Wagner - Hämatol.u.intern.Onkol. am Klinikum Fürth
Fürth, Germany
Onkologische Schwerpunktpraxis
Goslar, Germany
Universitätsklinikum Göttingen
Göttingen, Germany
Universitätsmedizin Greifswald
Greifswald, Germany
St. Antonius-Hospital Gronau GmbH
Gronau, Germany
Onkologische Schwerpunktpraxis
Hamburg, Germany
Asklepios Klinik Altona
Hamburg, Germany
Universitätsklinikum Heidelberg, Klinik für Urologie
Heidelberg, Germany
Urologie-Heinsberg
Heinsberg, Germany
Onkologische Praxis
Hildesheim, Germany
Universitätsklinikum des Saarlandes
Homburg, Germany
Universitätsklinikum Jena, Klinik für Urologie
Jena, Germany
Praxis für Urologie
Lauenburg, Germany
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.